AI Engines For more Details: Perplexity Kagi Labs You
Immunosuppression: Rapamycin is primarily used as an immunosuppressant medication to prevent rejection in organ transplantation, particularly kidney transplantation. It inhibits the activity of T lymphocytes, a type of white blood cell involved in the immune response, thereby reducing the risk of rejection.
Anti-proliferative Properties: Rapamycin has anti-proliferative properties, meaning it inhibits the growth and proliferation of cells. This property is exploited in the treatment of certain cancers, including renal cell carcinoma (RCC) and neuroendocrine tumors (NETs).
Coronary Stent Coating: Rapamycin is also used in drug-eluting stents (DES) deployed during percutaneous coronary intervention (PCI) procedures to prevent restenosis, the re-narrowing of arteries after stent placement. The drug-coated stents release rapamycin locally to inhibit the proliferation of smooth muscle cells in the arterial wall.
Lymphangioleiomyomatosis (LAM): Rapamycin has shown efficacy in the treatment of lymphangioleiomyomatosis, a rare lung disease characterized by the abnormal proliferation of smooth muscle cells in the lung tissue. It helps to stabilize lung function and reduce symptoms in patients with LAM.
Tuberous Sclerosis Complex (TSC): Rapamycin is also used in the treatment of tuberous sclerosis complex, a genetic disorder characterized by the growth of benign tumors in various organs, including the brain, kidneys, heart, eyes, lungs, and skin. It can reduce the size of tumors associated with TSC and improve symptoms.
Sirolimus-eluting Devices: Apart from drug-eluting stents, sirolimus has been incorporated into other medical devices, such as drug-eluting balloons and drug-eluting implants, for various applications in interventional cardiology and other fields.
Potential Anti-aging Effects: Rapamycin has been investigated for its potential anti-aging effects in preclinical studies. Some research suggests that rapamycin may extend lifespan and delay the onset of age-related diseases in certain model organisms, although further studies are needed to determine its safety and efficacy for anti-aging purposes in humans.
Side Effects: Common side effects of rapamycin include immunosuppression-related complications such as increased susceptibility to infections, as well as metabolic disturbances, gastrointestinal symptoms, skin reactions, and potential adverse effects on renal function and lipid metabolism. Patients receiving rapamycin therapy require close monitoring for these side effects.
Drug Interactions: Rapamycin may interact with other medications, particularly those metabolized by the cytochrome P450 system, potentially leading to altered drug concentrations and effects. Patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking to minimize the risk of drug interactions.
Rank | Probiotic | Impact |
---|---|---|
genus | Arthrobacter | Reduces |
order | Micrococcales | Reduces |
species | Limosilactobacillus reuteri | Increases |
species | Streptococcus thermophilus | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | -0.2 | |
Acne | 0.3 | 0.5 | -0.67 |
ADHD | 1.6 | 0.7 | 1.29 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | 0 |
Allergic Rhinitis (Hay Fever) | 0.9 | -0.9 | |
Allergies | 0.7 | 0.7 | 0 |
Allergy to milk products | 1.4 | 0.2 | 6 |
Alopecia (Hair Loss) | 0.3 | 0.3 | |
Alzheimer's disease | 2 | 2.9 | -0.45 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 1 | -2.33 |
Ankylosing spondylitis | 1.8 | 1.2 | 0.5 |
Anorexia Nervosa | 0.4 | 1.8 | -3.5 |
Antiphospholipid syndrome (APS) | 0.7 | 0.6 | 0.17 |
Asthma | 0.4 | 1.4 | -2.5 |
Atherosclerosis | 0.9 | -0.9 | |
Atrial fibrillation | 0.8 | 0.6 | 0.33 |
Autism | 5.1 | 1.5 | 2.4 |
Autoimmune Disease | 0.2 | 0.2 | |
Barrett esophagus cancer | 0.6 | 0.2 | 2 |
benign prostatic hyperplasia | 0.3 | -0.3 | |
Bipolar Disorder | 0.8 | 1 | -0.25 |
Brain Trauma | 1.4 | 1.2 | 0.17 |
Breast Cancer | 0.3 | 0.5 | -0.67 |
Carcinoma | 1.6 | 2.4 | -0.5 |
Celiac Disease | 2.5 | 0.8 | 2.13 |
Cerebral Palsy | 1.2 | 1.3 | -0.08 |
Chronic Fatigue Syndrome | 0.8 | 1.6 | -1 |
Chronic Kidney Disease | 1.4 | -1.4 | |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2.2 | 2.1 | 0.05 |
Chronic Urticaria (Hives) | 0.4 | 0.6 | -0.5 |
Coagulation / Micro clot triggering bacteria | 1.1 | 2.7 | -1.45 |
Colorectal Cancer | 1.2 | 0.6 | 1 |
Constipation | 1.3 | 0.5 | 1.6 |
Coronary artery disease | 0.6 | 0.4 | 0.5 |
COVID-19 | 4.6 | 3.7 | 0.24 |
Crohn's Disease | 1.9 | 2.3 | -0.21 |
cystic fibrosis | 0.8 | -0.8 | |
deep vein thrombosis | 1.1 | 0.7 | 0.57 |
Depression | 5.1 | 5.2 | -0.02 |
Dermatomyositis | 0.3 | 0.6 | -1 |
Eczema | 1.3 | 0.3 | 3.33 |
Endometriosis | 1.1 | 1 | 0.1 |
Eosinophilic Esophagitis | 1.4 | -1.4 | |
Epilepsy | 0.9 | 1.2 | -0.33 |
erectile dysfunction | 0.3 | 0.3 | 0 |
Fibromyalgia | 0.8 | 0.3 | 1.67 |
Functional constipation / chronic idiopathic constipation | 2.1 | 0.7 | 2 |
gallstone disease (gsd) | 0.5 | 1.1 | -1.2 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 0.4 | 5 |
Generalized anxiety disorder | 0.3 | 0.3 | |
giant cell arteritis | 0.3 | -0.3 | |
Glioblastoma | 1.3 | 0.5 | 1.6 |
Gout | 0.6 | -0.6 | |
Graves' disease | 0.3 | 3.3 | -10 |
Halitosis | 1 | 0.4 | 1.5 |
Hashimoto's thyroiditis | 1.4 | 1.4 | |
Hemorrhoidal disease, Hemorrhoids, Piles | 1 | 1 | |
Hidradenitis Suppurativa | 0.5 | 0.8 | -0.6 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.5 | 0.2 | 1.5 |
hypercholesterolemia (High Cholesterol) | 1.9 | 0.2 | 8.5 |
hyperglycemia | 0.9 | 0.2 | 3.5 |
hypersomnia | 0.2 | -0.2 | |
hypertension (High Blood Pressure | 1.3 | 4.2 | -2.23 |
Hypothyroidism | 0.3 | 0.5 | -0.67 |
Hypoxia | 0.2 | 0.2 | |
IgA nephropathy (IgAN) | 0.4 | 0.5 | -0.25 |
Inflammatory Bowel Disease | 1 | 2.4 | -1.4 |
Insomnia | 0.4 | 2 | -4 |
Intelligence | 1.8 | 1.8 | |
Intracranial aneurysms | 0.5 | 0.5 | |
Irritable Bowel Syndrome | 1.8 | 1.3 | 0.38 |
Liver Cirrhosis | 3.2 | 3.4 | -0.06 |
Long COVID | 6.8 | 4.2 | 0.62 |
Low bone mineral density | 1 | -1 | |
Lung Cancer | 0.8 | -0.8 | |
ME/CFS with IBS | 0.8 | -0.8 | |
ME/CFS without IBS | 0.6 | -0.6 | |
Metabolic Syndrome | 5.3 | 5.5 | -0.04 |
Mood Disorders | 7 | 6.8 | 0.03 |
multiple chemical sensitivity [MCS] | 1 | -1 | |
Multiple Sclerosis | 1.3 | 2.9 | -1.23 |
Multiple system atrophy (MSA) | 0.3 | 0.2 | 0.5 |
Neuropathy (all types) | 1.5 | 1.2 | 0.25 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | -0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.5 | 2.9 | -0.93 |
Obesity | 3.1 | 4.4 | -0.42 |
obsessive-compulsive disorder | 1.2 | 2.5 | -1.08 |
Osteoarthritis | 0.3 | 0.6 | -1 |
Osteoporosis | 0.2 | 0.6 | -2 |
pancreatic cancer | 0.3 | 0.6 | -1 |
Parkinson's Disease | 3.8 | 2.7 | 0.41 |
Polycystic ovary syndrome | 0.3 | 2.4 | -7 |
primary biliary cholangitis | 0.3 | 0.3 | 0 |
Psoriasis | 1.4 | 2.2 | -0.57 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.3 | 3.1 | 0.39 |
Rosacea | 0.4 | 0.5 | -0.25 |
Schizophrenia | 2.6 | 2.8 | -0.08 |
scoliosis | 1.2 | 1.2 | |
sensorineural hearing loss | 0.3 | -0.3 | |
Sjögren syndrome | 0.2 | 1.3 | -5.5 |
Sleep Apnea | 0.8 | 0.8 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 1.1 | -0.38 |
Stress / posttraumatic stress disorder | 1.2 | 2.4 | -1 |
Systemic Lupus Erythematosus | 1.4 | 2.9 | -1.07 |
Tic Disorder | 1.3 | 0.4 | 2.25 |
Tourette syndrome | 0.4 | -0.4 | |
Type 1 Diabetes | 1 | 2.5 | -1.5 |
Type 2 Diabetes | 3.6 | 3.1 | 0.16 |
Ulcerative colitis | 3.5 | 1.8 | 0.94 |
Unhealthy Ageing | 0.5 | 1.6 | -2.2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.